GET DAILY SIGNALSSunshine Biopharma (SBFM) Q3 2026 Results: Revenue Holds Steady as Losses Expand
Key Takeaways
- Sunshine Biopharma (SBFM) reported third-quarter 2026 revenue of about $9.44 million, nearly flat compared with $9.42 million in the same period a year earlier.
- The company posted a net loss of roughly $1.22 million for the quarter, widening from a net loss of about $0.88 million in Q3 2025.
- Gross profit held steady near $3.1 million, but rising general and administrative (G&A) costs pushed the operating loss higher year over year.
- Cash and cash equivalents climbed to approximately $14.6 million, reflecting equity financing and warrant exercises completed earlier in the year.
- The company's accumulated deficit continued to grow, underscoring its unprofitable position despite a stronger balance sheet.
- For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages linked here.
- To discover fresh trading ideas across the market, explore Trending AI Robots.
Why These Earnings Matter in Context
Sunshine Biopharma is a micro-cap pharmaceutical company focused on developing and commercializing oncology and antiviral drugs. Its quarterly earnings matter because the company is navigating a difficult stretch of repeated losses, a declining share price, and heavy dilution from equity raises and warrant exercises. Investors closely watch whether revenue can stabilize and whether cash reserves remain sufficient to fund operations and drug development. Coming into this report, the prior quarter had delivered a modest revenue beat, but the company still faced pressure on profitability and its Nasdaq listing. The Q3 2026 results, filed with the U.S. Securities and Exchange Commission (SEC) on November 12, 2026, offer a fresh read on those challenges.
Breaking Down the Reported Figures
For the third quarter ended September 30, 2026, Sunshine Biopharma reported revenue of $9,442,325, essentially flat compared with $9,417,179 in the prior-year quarter. Gross profit was $3,101,702, up only slightly from $3,073,540 a year earlier, reflecting a gross margin near 33%. The company's net loss widened to $1,223,940, compared with a net loss of $883,820 in Q3 2025, as higher general and administrative expenses offset any top-line stability.
For the first nine months of 2026, revenue totaled $26,794,777, down from $27,728,750 in the same period of 2025, while the nine-month net loss widened to $4,031,857 from $3,834,425 a year earlier. Revenue came in slightly below the roughly $9.6 million consensus estimate tracked by several financial data providers, though the company's thin analyst coverage makes precise comparisons less meaningful. On the balance sheet, cash and cash equivalents rose to about $14.6 million as of September 30, 2026, up from $9.1 million at year-end 2025, supported by roughly $7.3 million in net proceeds from a public offering and about $2.7 million from warrant exercises. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Potential Market Reaction and Sentiment
Sunshine Biopharma is a thinly traded micro-cap, so post-earnings price action can be volatile and driven as much by share structure and liquidity as by fundamentals. The Q3 2026 report presented a mixed picture: revenue held roughly flat while the net loss widened, which may weigh on sentiment, yet the company's materially stronger cash position offers some reassurance about near-term funding. Investors are also digesting the impact of significant dilution, a recent reverse stock split, and a substantially increased share count. Rather than a single headline number, the market is likely to focus on whether the company can begin converting its cash runway into revenue growth and progress toward narrowing losses.
Key Factors to Monitor Ahead
Looking ahead, investors should watch whether Sunshine Biopharma can reaccelerate revenue growth. Nine-month revenue declined year over year, and a flat third quarter does not yet signal a durable turnaround. Demand for its core pharmaceutical products and any new commercialization or partnership activity will be central to the story.
Cost discipline is another key factor. General and administrative expenses rose during the quarter, and the company's accumulated deficit continues to climb. Even with a stronger cash position, sustained operating losses could pressure the balance sheet again, so progress on narrowing expenses relative to revenue will matter.
Finally, monitor capital-structure developments. The company has relied on equity offerings and warrant exercises to fund operations, which has diluted existing shareholders and driven a large increase in shares outstanding. Any additional financing, changes to the share count, or updates on Nasdaq listing compliance will be important signals. As with any micro-cap pharmaceutical name, results and share movements can shift quickly, so investors should track official filings and disclosures closely.
My Experience with Tickeron’s AI Screener
In my own research process, I often turn to Tickeron’s AI Screener when evaluating names like this one. It lets me quickly filter for technical patterns, fundamentals, and sector comparisons, which helps surface context I might otherwise miss. The tool has become a regular part of how I cross-check small-cap opportunities before digging deeper into filings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SBFM's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SBFM turned positive on October 23, 2026. Looking at past instances where SBFM's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for SBFM's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +5.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBFM advanced for three days, in 117 of 166 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SBFM as a result. In 86 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBFM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SBFM entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.382) is normal, around the industry mean (6.379). P/E Ratio (-0.296) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.070) is also within normal values, averaging (183.387).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. SBFM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBFM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement